

Anti-hTIGIT-hIgG1fut

Non-fucosylated monoclonal human IgG1 antibody against human TIGIT

Catalog code: htigit-mab13

<https://www.invivogen.com/nonfuco-anti-htigit-mab>

For research use only, not for diagnostic or therapeutic use

Version 19J24-ED

PRODUCT INFORMATION

Contents:

- 100 µg of Anti-hTIGIT-hIgG1fut, provided azide-free and lyophilized

Target: TIGIT (T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain)

Species reactivity: Human

Source: CHO cells (deficient for fucosylation)

Isotype: Human IgG1

Light chain type: Kappa

Clonality: Monoclonal

Purification: By affinity chromatography with protein G

Formulation: 0.2 µm filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Storage

- Product is shipped at room temperature. Store lyophilized antibody at -20°C. Lyophilized product is stable for at least 1 year.
- Reconstituted antibody is stable for 1 month when stored at 4°C and for 1 year when aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

Quality control


- Binding of Anti-hTIGIT-hIgG1fut to human TIGIT on target cells has been confirmed using flow cytometry.
- The complete sequence of the antibody has been verified.
- Absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and TLR4 cellular assays.

PRODUCT DESCRIPTION

Anti-hTIGIT-hIgG1fut is a recombinant monoclonal antibody (mAb) featuring a variable region that recognizes human TIGIT, an inhibitory immune checkpoint, and a non-fucosylated constant region of the human IgG1 isotype (hIgG1fut). Anti-hTIGIT-hIgG1fut was generated by recombinant DNA technology, produced in CHO cells (deficient for fucosylation), and purified by affinity chromatography with protein G.

TIGIT - the Immune checkpoint

TIGIT (T cell immunoglobulin and ITIM domain) is an inhibitory checkpoint that has been implicated in tumor immunosurveillance¹. TIGIT is specifically expressed on immune cells including, natural killer (NK) cells, activated T cells, memory T cells, and a subset of regulatory T cells (Treg). TIGIT binds to CD155 (PVR) and CD112 (PVRL2, nectin-2), which are expressed on antigen-presenting cells (APCs), T cells, and a variety of non-hematopoietic cells including tumor cells. Interestingly, TIGIT competes with CD226 (also known as DNAM-1) and CD96 (also known as Tactile) for the same ligands^{1,2}.



Upon binding to its ligand, phosphorylation of TIGIT inhibits the NF-κB, P13K, and MAPK pathways, and leads to a strong reduction of NK cytotoxicity². Additionally, TIGIT directly induces T cell inhibition by blocking activation, proliferation, and effector functions³.

Due to low expression of TIGIT in peripheral lymphoid organs and highly enriched in tumor infiltrating lymphocytes (TILs), the established synergy of TIGIT with other co-inhibitory immune checkpoints, and its ligands being widely expressed on tumor cells, the blockade of TIGIT is highly favorable in cancer immunotherapy^{1,2}. The dual blockade of TIGIT and PD-L1 has shown synergistic effects in a murine tumor model, resulting in complete tumor rejection and induced protective memory responses. A similar synergistic effect has been noted with PD-1 and Tim-3^{1,2}. Interestingly, TIGIT's role in the tumor microenvironment (TME) may also be intertwined with the microbiome. The suppressive function of TIGIT is also exploited by a bacterium commonly found in the TME *Fusobacterium nucleatum*, to inhibit protective immune responses⁴.

IgG1fut Isotype effector function

Anti-hTIGIT-hIgG1fut is a non-fucosylated antibody. The absence of the fucose residue from the N-glycans of the IgG-Fc results in an enhancement of antibody-dependent cellular cytotoxicity (ADCC) without any detectable change to complement-dependent cytotoxicity (CDC) or antigen binding capability (see reverse side).

1. Solomon, B. L. *et al.* 2018. TIGIT: a novel immunotherapy target moving from bench to bedside. *Cancer Immunol Immunother* 67, 1659-1667. 2. Anderson, A.C. *et al.* 2016. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. *Immunity* 44, 989-1004. 3. Joller, N. *et al.* 2011. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. *J Immunol* 186, 1338-1342. 4. Gur, C. *et al.* 2015. Binding of the Fap2 protein of *Fusobacterium nucleatum* to human inhibitory receptor TIGIT protects tumors from immune cell attack. *Immunity* 42, 344-355.

METHODS

Anti-hTIGIT-hIgG1fut resuspension (200 µg/ml)

Note: Ensure you see the lyophilized pellet before resuspension.

- Add 500 µl of sterile water to the vial and gently pipette until completely resuspended
- Prepare aliquots and store at -20°C until required

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com

 **InvivoGen**
www.invivogen.com

ANTIBODY ISOTYPE COLLECTION

For your research, InvivoGen provides an **Anti-hTIGIT isotype family**. This collection consists of mAbs comprising the variable region of human TIGIT, and differing constant regions of both native and engineered human isotype IgG1. The isotypes differ in their functional and effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement dependent cytotoxicity (CDC), as presented in the table below. The Anti-hTIGIT isotype family will assist you in the study of the various effector functions of the different isotypes, and help you determine which isotype is the most suitable for your application.

Effector functions of both native and engineered IgG1 isotypes

Effector functions	Native	Engineered	
	IgG1	IgG1NQ	IgG1fut
ADCC	++	-	++++
ADCP	+++	-	+++
CDC	++	+/-	++

RELATED PRODUCTS

Product	Catalog Code
Anti-hTIGIT-hlgG1	htigit-mab1
Anti-hTIGIT-hlgG1NQ	htigit-mab12
Anti-hPD-L1-hlgG1	hpd11-mab1
Jurkat-Lucia™ NFAT-CD16 cells	jkt1-nfat-cd16
QUANTI-Luc™	rep-qlc1

Note: For more information regarding InvivoGen's ADCC assay please visit our website <https://www.invivogen.com/adcc>